ENDRA Life Sciences (NASDAQ:NDRA) Stock Price Down 7.1% – Here’s What Happened

ENDRA Life Sciences Inc. (NASDAQ:NDRA) shares traded down 7.1% on Friday. The company traded as low as $4.74 and last traded at $4.74. Approximately 14,349 shares traded hands during trading, a decline of 42% from the average daily volume of 24,664 shares. The stock had previously closed at $5.10.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised ENDRA Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, ENDRA Life Sciences currently has an average rating of “Hold” and an average price target of $25.00.

ENDRA Life Sciences Stock Performance

The firm’s fifty day simple moving average is $5.41 and its 200 day simple moving average is $5.16. The firm has a market cap of $7.11 million, a P/E ratio of -0.74 and a beta of -0.09.

ENDRA Life Sciences (NASDAQ:NDRA) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.21. On average, equities research analysts predict that ENDRA Life Sciences Inc. will post -4.11 earnings per share for the current year.

Hedge Funds Weigh In On ENDRA Life Sciences

A hedge fund recently bought a new stake in ENDRA Life Sciences stock. Citizens Financial Group Inc. RI acquired a new position in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 28,400 shares of the company’s stock, valued at approximately $151,000. Citizens Financial Group Inc. RI owned approximately 2.24% of ENDRA Life Sciences at the end of the most recent reporting period. Institutional investors and hedge funds own 1.19% of the company’s stock.

About ENDRA Life Sciences

ENDRA Life Sciences Corp. (NASDAQ: NDRA) is a medical technology company developing noninvasive diagnostic imaging systems. The company’s primary technology is Thermo-Acoustic Enhanced UltraSound (TAEUS), a platform designed to expand the capabilities of conventional ultrasound by using radiofrequency energy and ultrasound imaging to characterize tissue properties.

ENDRA is initially focused on applying TAEUS to the assessment of liver fat, including fatty liver disease. Its system is intended to provide quantitative information about hepatic steatosis and potentially other tissue characteristics without requiring an invasive biopsy or the use of more costly imaging modalities.